Summary
Cardinal Health, Inc. reported solid revenue growth for the quarter ended December 31, 2007, with a 7% increase year-over-year, driven by pharmaceutical price appreciation and volume increases, as well as contributions from recent acquisitions. While revenue climbed, the company faced increased selling, general, and administrative (SG&A) expenses and higher restructuring and acquisition integration charges, which tempered operating earnings growth to a more modest 1% increase. Net earnings saw a significant decrease of 56% compared to the prior year, largely influenced by a substantial one-time gain from discontinued operations in the prior year's comparable period. The company continued its share repurchase program, indicating confidence in its financial position and a commitment to returning value to shareholders. Investors should note the ongoing legal proceedings and the DEA matter, which present potential risks and uncertainties for future operations.
Key Highlights
- 1Revenue increased by 7% to $23.3 billion for the quarter ended December 31, 2007, compared to the prior year, driven by pharmaceutical price appreciation and increased volume.
- 2Operating earnings saw a modest increase of 1% to $519.2 million, despite higher SG&A expenses and special charges.
- 3Net earnings decreased significantly by 56% to $324.7 million, primarily due to a large gain from discontinued operations in the prior year's period.
- 4The company continued its share repurchase program, buying back approximately $350 million of its common stock during the quarter.
- 5Significant litigation and regulatory matters are ongoing, including a DEA investigation related to controlled substance distribution and a voluntary recall of Alaris Pump modules.
- 6The company adopted FIN No. 48, "Accounting for Uncertainty in Income Taxes," which resulted in a $139.3 million reduction in retained earnings.
- 7Segment profit declined in the Pharmaceutical and Medical Supply Chain Services segments but grew substantially in Clinical Technologies and Services and Medical Products and Technologies.